Evidence map›Paper›PMID 32172432›Full record

ArticleFamilial cancer2020

Lack of evidence for CDK12 as an ovarian cancer predisposing gene.

Alexandre Eeckhoutte, Mathilde Saint-Ghislain, Manon Reverdy, Virginie Raynal, Sylvain Baulande, Guillaume Bataillon, Lisa Golmard, Dominique Stoppa-Lyonnet, Tatiana Popova, Claude Houdayer and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexandre EeckhoutteInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France.
Mathilde Saint-GhislainInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France.
Manon ReverdyInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France.
Virginie RaynalInserm U830, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75248, Paris, France.
Sylvain BaulandeNGS Platform, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75248, Paris, France.
Guillaume BataillonDepartment of Biopathology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75248, Paris, France.
Lisa GolmardInstitut Curie, Hôpital, Service de Génétique, 26 Rue d'Ulm, 75248, Paris, France.
Dominique Stoppa-LyonnetInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France.
Tatiana PopovaInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France.
Claude HoudayerInstitut Curie, Hôpital, Service de Génétique, 26 Rue d'Ulm, 75248, Paris, France.
Elodie ManiéInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France.
Marc-Henri SternInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisee par la Ligue Nationale Contre le Cancer, Institut Curie, 26 Rue d'Ulm, 75248, Paris, France. marc-henri.stern@curie.fr.ORCID 0000-0002-8100-2272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CDK12 variants were investigated as a genetic susceptibility to ovarian cancer in a series of 416 unrelated and consecutive patients with ovarian carcinoma and who carry neither germline BRCA1 nor BRCA2 pathogenic variant. The presence of CDK12 variants was searched in germline DNA by massive parallel sequencing on pooled DNAs. The lack of detection of deleterious variants and the observed proportion of missense variants in the series of ovarian carcinoma patients as compared with all human populations strongly suggests that CDK12 is not an ovarian cancer predisposing gene.

Indexed as

Genes, Tumor SuppressorGenetic Predisposition to DiseaseGenetic VariationCyclin-Dependent KinasesFemaleGenes, BRCA1Genes, BRCA2Genetic ProfileGerm-Line MutationHigh-Throughput Nucleotide SequencingHumansMiddle AgedOvarian NeoplasmsCDK12 protein, humanCyclin-Dependent KinasesCancer susceptibilityCDK12NGSOvarian carcinomaPool sequencing

Identifiers

PMID32172432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.